Literature DB >> 11127935

Phospholamban and cardiac contractility.

K Frank1, E G Kranias.   

Abstract

Over the last three decades, our knowledge and understanding of the role of phospholamban and its modulation of sarcoplasmic reticulum (SR) function has advanced significantly. Phospholamban is a key regulator of cardiac contractility and modulates SR Ca2+ sequestration by inhibiting the SR Ca2+-ATPase (SERCA) in its dephosphorylated state. Upon phosphorylation, which is mediated through beta-adrenergic stimulation, the inhibitory effect of phospholamban on the function of SERCA is relieved. This review summarizes recent advances that have been made towards understanding the modulation of SR Ca2+-sequestration by phospholamban through the generation and characterization of genetically altered animal models. It also discusses the role of phospholamban in human heart failure and recent attempts to restore SR function in experimentally induced and human heart failure, which may be translated into future therapeutic approaches in the treatment of this disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11127935     DOI: 10.3109/07853890008998837

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  29 in total

Review 1.  Targeting calcium cycling proteins in heart failure through gene transfer.

Authors:  Federica del Monte; Roger J Hajjar
Journal:  J Physiol       Date:  2003-01-01       Impact factor: 5.182

2.  Cardiac disease in mucopolysaccharidosis type I attributed to catecholaminergic and hemodynamic deficiencies.

Authors:  Nathan J Palpant; Fikru B Bedada; Brandon Peacock; Bruce R Blazar; Joseph M Metzger; Jakub Tolar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-11-12       Impact factor: 4.733

Review 3.  Ion Channels in the Heart.

Authors:  Daniel C Bartos; Eleonora Grandi; Crystal M Ripplinger
Journal:  Compr Physiol       Date:  2015-07-01       Impact factor: 9.090

Review 4.  Treating heart failure with cardiac contractility modulation electrical signals.

Authors:  Hani N Sabbah; Ramesh C Gupta; Sharad Rastogi; Sudhish Mishra; Yuval Mika; Daniel Burkhoff
Journal:  Curr Heart Fail Rep       Date:  2006-04

5.  SERCA2a superinhibition by human phospholamban triggers electrical and structural remodeling in mouse hearts.

Authors:  Hong-Sheng Wang; Demetrios A Arvanitis; Min Dong; Paul J Niklewski; Wen Zhao; Chi Keung Lam; Evangelia G Kranias; Despina Sanoudou
Journal:  Physiol Genomics       Date:  2011-01-25       Impact factor: 3.107

6.  PHD2/3-dependent hydroxylation tunes cardiac response to β-adrenergic stress via phospholamban.

Authors:  Liang Xie; Xinchun Pi; W H Davin Townley-Tilson; Na Li; Xander H T Wehrens; Mark L Entman; George E Taffet; Ashutosh Mishra; Junmin Peng; Jonathan C Schisler; Gerhard Meissner; Cam Patterson
Journal:  J Clin Invest       Date:  2015-06-15       Impact factor: 14.808

7.  Adrenergic regulation of cardiac contractility does not involve phosphorylation of the cardiac ryanodine receptor at serine 2808.

Authors:  Scott M MacDonnell; Gerardo García-Rivas; Joseph A Scherman; Hajime Kubo; Xiongwen Chen; Héctor Valdivia; Steven R Houser
Journal:  Circ Res       Date:  2008-04-03       Impact factor: 17.367

8.  Ca2+ binding to site I of the cardiac Ca2+ pump is sufficient to dissociate phospholamban.

Authors:  Zhenhui Chen; Brandy L Akin; Larry R Jones
Journal:  J Biol Chem       Date:  2009-11-30       Impact factor: 5.157

Review 9.  Molecular basis of diastolic dysfunction.

Authors:  Muthu Periasamy; Paul M L Janssen
Journal:  Heart Fail Clin       Date:  2008-01       Impact factor: 3.179

Review 10.  The Role of Cullin-RING Ligases in Striated Muscle Development, Function, and Disease.

Authors:  Jordan Blondelle; Andrea Biju; Stephan Lange
Journal:  Int J Mol Sci       Date:  2020-10-26       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.